Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perchlorate SCHEMBL15796714 | 0.94 | — | — | |
| SCHEMBL15803038 | 0.89 | — | — | |
| SCHEMBL637001 | 0.87 | NCEH1 (0.34) | NCEH1 | |
| SCHEMBL635987 | 0.83 | CYP2A6 (0.37) | NCEH1MAPT | |
| SCHEMBL30894429 | 0.81 | GPR84 (0.32) | — | |
| SCHEMBL16424524 | 0.79 | MAPT (0.35) | MAPT | |
| SCHEMBL636477 | 0.78 | CYP1A2 (0.33) | MAPT | |
| Hydrochloric Acid SCHEMBL635451 | 0.78 | CYP1A2 (0.33) | MAPT | |
| SCHEMBL635100 | 0.78 | ATM (0.35) | NCEH1MAPT | |
| SCHEMBL16351499 | 0.75 | GABRA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1927596-B9 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2013-05-15 | — | — | EP | claimed |
| EP-1927596-B1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | claimed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | claimed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | claimed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | claimed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10710989-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-14 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-1927596-B1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | disclosed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | SIGMAR1 3571/4885NCEH1 3285/4885MAPT 3660/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | SIGMAR1 3571/4885NCEH1 3285/4885MAPT 3660/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | SIGMAR1 3571/4885NCEH1 3285/4885MAPT 3660/4885 |
| US-10710989-B2 | Method for producing heterocyclic compound | APP, THOP1, TALDO1 | SIGMAR1 4161/4885NCEH1 448/4885MAPT 16/4885 |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | MVD, C5, C1S | SIGMAR1 2338/4885NCEH1 3673/4885MAPT 4851/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | SIGMAR1 3571/4885NCEH1 3285/4885MAPT 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.